Toll-like receptor 7/8-matured RNA-transduced dendritic cells as post-remission therapy in acute myeloid leukaemia: results of a phase I trial
/in Acute Leukemia, Dendritic Cells, International Publications /von 2020-03-03 / Clin Transl Immunology 2020;9(3):e1117Consensus guidelines for the definition, detection and interpretation of immunogenic cell death
/in Dendritic Cells, Immunogenic Cell Death, International Publications, Newcastle Disease Virus, Prostate Cancer /von 2020-03-01 / J Immunother Cancer 2020 03;8(1)T cell receptor repertoire characteristics both before and following immunotherapy correlate with clinical response in mesothelioma
/in Dendritic Cells, International Publications, Malignant Pleural Mesothelioma /von 2020-03-01 / J Immunother Cancer 2020 Mar;8(1)Photodynamic Therapy-Based Dendritic Cell Vaccination Suited to Treat Peritoneal Mesothelioma
/in Dendritic Cells, International Publications, Malignant Pleural Mesothelioma /von 2020-02-27 / Cancers (Basel) 2020 Feb;12(3)Targeting STAT3 enhances NDV-induced immunogenic cell death in prostate cancer cells
/in Immunogenic Cell Death, International Publications, Newcastle Disease Virus, Prostate Cancer /von 2020-02-26 / J Cell Mol Med 2020 04;24(7):4286-4297Oncolytic Newcastle disease virus activation of the innate immune response and priming of antitumor adaptive responses in vitro
/in International Publications, Newcastle Disease Virus /von 2020-02-22 / Cancer Immunol. Immunother. 2020 Jun;69(6):1015-1027Immunotherapy in Malignant Pleural Mesothelioma
/in Dendritic Cells, International Publications, Malignant Pleural Mesothelioma /von 2020-02-21 / Front Oncol 2020;10:187[The adjuvant killing effect of modulated electro-hyperthermia combined with chemotherapy on B16F10 melanoma cells]
/in Hyperthermia, International Publications, Malignant Melanoma /von 2020-02-21 / Magy Onkol 2021 Mar;65(1):71-77Tumor-associated antigen-based personalized dendritic cell vaccine in solid tumor patients
/in Dendritic Cells, International Publications /von 2020-02-20 / Cancer Immunol. Immunother. 2020 Jul;69(7):1375-1387
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de